SolAeroMed is a leading brand specializing in the development of innovative biophysical respiratory drugs and delivery devices. With a mission to provide effective treatments for various obstructive lung diseases, such as Cystic Fibrosis, Bronchiectasis, Asthma, and Chronic Obstructive Lung Disease, SolAeroMed aims to improve the lives of patients worldwide. At the forefront of their product lineup is S-1226, a groundbreaking respiratory drug that is currently undergoing Phase II clinical trials.

This patented drug has the potential to revolutionize the treatment of Cystic Fibrosis, Bronchiectasis, Asthma, and even COVID-19. Additionally, SolAeroMed is also developing S-1229, a promising treatment for surfactant dysfunction, which is currently in pre-clinical development. As an industry leader, SolAeroMed actively seeks partnerships for the development of cutting-edge therapies and delivery devices for biophysical respiratory drugs.

With a dedicated team of experts, including a board of directors and advisors, SolAeroMed is committed to advancing respiratory care and improving patient outcomes. Stay informed about their latest advancements and news through their website and sign up for their newsletter to stay up to date with their exciting developments